Glioblastoma Therapeutics Network (GTN; U19 Clinical Trial Required)
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them
| Agency | National Institutes of Health |
|---|---|
| Status | Forecasted |
| Opportunity number | RFA-CA-25-033 |
| Posted date | 09/17/2025 |
| Who can apply | Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations; |
| Assistance Listing (CFDA) | 93.394, 93.395 |
| Description | Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for research on novel therapies for adult glioblastoma (GBM). The goal is to improve the treatment of adult GBM by developing novel effective agents that can cross the blood brain barrier (BBB) and testing them clinically. Successful early-stage trials of new drugs from this NOFO would transition seamlessly to later stage trials using well-established NCI clinical trial mechanisms. To implement this concept, a highly collaborative GBM Therapeutics Network (GTN) of cross-cutting teams will be established, each team capable of driving therapeutic agent(s) from pre-clinical development, through IND studies, into pilot clinical studies in humans. Appropriate therapeutic agents include: |
| Agency contact | forryscs@mail.nih.gov |
| Official listing | https://www.grants.gov/search-results-detail/360606 |